A Guide to Year-Round Allergy Management

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...
- Advertisement -

Seasonal allergies can be frustrating enough. Pollen from grass, weeds, and trees can result in all manner of uncomfortable symptoms in specific seasons. However, we should be sparing a thought for anyone experiencing year-round allergies. Not only can they be affected by the same seasonal allergens, but also allergens that are present year-round. Whether you or someone you know is living with year-round allergies, you might find management techniques and general helpful advice below.

What Are Year-Round Allergies?

Most people have no trouble receiving a diagnosis for year-round allergies. Also known as perennial allergies, they affect people year-round, not just when pollen levels are high. Alongside being allergic to tree, grass, and weed pollen, you might react to other everyday indoor and outdoor allergens, such as mold, pet dander, and dust mites. Many people with perennial allergies, a form of allergic rhinitis, experience the following:

  • Sneezing
  • Runny nose
  • Nasal congestion
  • Wheezing
  • Coughing
  • Itchy eyes
  • Watery eyes
  • Itchy mouth
  • Itchy throat

The severity of these symptoms can often depend on the allergen and its volume. For example, some people might experience severe reactions in winter when mold is sometimes more abundant.

Visit An Allergist

When you continually combat allergy-related symptoms, consider a trip to an allergist. Allergists are medical practitioners specializing in allergy diagnosis and treatment. Depending on your presenting symptoms and level of discomfort, allergists might do the following things:

  • Perform allergy testing to identify the problematic allergens
  • Offer prevention education to learn how to avoid triggers
  • Prescribe medication to treat allergies
  • Offer immunotherapy in the form of shots or tablets

Preventative Measures for Year-Round Allergies

Medication and allergy shots can be excellent ways to manage uncomfortable symptoms associated with year-round allergies. However, you might be able to prevent some of those symptoms in the first place. Allergists typically provide information on preventative actions you can take to limit your exposure. These actions can then result in symptom reduction.

Remove Dust-Collecting Items

You might enjoy having your favorite ornaments and books on display, but a dust allergy might mean you must make sacrifices. Sometimes, people experience a reduction in their allergy symptoms by removing anything that can collect dust in their homes. Books, magazines, and ornaments can all be havens for dust.

Replace Curtains With Blinds

The average person won’t give their curtains much thought when cleaning their homes. However, even with regular cleaning, curtains can accumulate dust mites and other allergens. Rather than washing your curtains frequently, consider replacing them with blinds. Blinds featuring wipe-down material can be much cleaner while potentially keeping your allergy symptoms at bay.

Make Housecleaning Your Priority

Surveys have revealed that one in six Americans won’t clean their homes for at least a month. One in 10 even admitted to not cleaning their homes for six months. When you experience year-round allergies, having a clean home is important.

At the very least, you might prioritize dusting, vacuuming, and mopping. These tasks can keep dust levels to a minimum. If you can’t find time for regular cleaning, outsource household chores to a cleaning company.

Use Air Conditioners and Dehumidifiers

Excellent air quality is important when you have allergies. The higher the indoor humidity levels, the more dust mites can be present. Air conditioners and dehumidifiers might be able to help. Ensure these feature high-efficiency particulate air (HEPA) filters to remove as many harmful particles from the air as possible.

Limit Pet Movement

A pet dander allergy means you’re allergic to the protein in animal dander, saliva, and urine. However, fur, hair, and feathers can collect these allergens and carry others, like pollen and dust mites. Not everyone knows they have a pet dander allergy until they own pets. By then, you can grow attached to your pets and prefer not to rehome them.

If rehoming your pet is not an option, consider limiting their movement in your home. This action might improve your comfort levels. Keep them out of bedrooms and assign them a dedicated bed in a shared space. You can also wash your pet frequently and see if that makes a difference.

Treatment Options for Year-Round Allergies

Treatment options for year-round allergies can depend on allergy severity, what they are, and your allergist. They might also recommend multiple treatment options to manage numerous symptoms simultaneously. Corticosteroid nasal sprays and nasal-metered dose inhalers may treat symptoms like sneezing, congestion, and nasal passage swelling. Your allergist might also recommend taking corticosteroid nasal sprays with antihistamines.

Sometimes, antihistamine-decongestant combinations in single tablet form can be a recommendation. However, medical professionals don’t recommend this treatment option for everyone. It may not be suitable for people with high blood pressure, young children, or those using specific antidepressants.

Allergen Immunotherapy

Over-the-counter and prescribed medications help many people manage their seasonal and perennial allergies. However, allergen immunotherapy can sometimes be an option worth exploring. Immunotherapy describes building up your tolerance to specific allergens. These are introduced in small doses over time, normally via injection or under the tongue.

Allergen immunotherapy aims to help your body get used to an allergen being around. With time, your body might develop immunity or, at least, tolerance. Immunotherapy is about playing the long game. You won’t notice symptom changes overnight. Many people exploring this option see improvements within their first year of treatment. Those improvements can continue over multiple years.

When to See an Allergist

It’s easy to think that you should just put up with allergy symptoms. The occasional case of itchy eyes or a runny nose can be manageable. Still, not all allergy symptoms are. It can be important to seek professional help when:

  • Your symptoms last several months
  • Your allergies cause breathing difficulties and chronic sinus infections
  • Over-the-counter medications aren’t working
  • Your everyday activities are affected
  • You’re often short of breath
  • You’ve been diagnosed with asthma
  • You’re experiencing serious asthma warning signs
  • Your quality of life has decreased

Year-round allergies can be challenging to manage, especially when combating many symptoms simultaneously. Now that you’re well-informed about perennial allergies and treatments, you can take steps to regain control of your health.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »